Bourne Partners Strategic Capital Mergers and Acquisitions Summary

Private Equity Firm Profile

Bourne Partners Strategic Capital’s most common sectors for investment arelife science (80%) and healthcare services (20%) . The Firm’s most common investment types include buyout (lbo, mbo, mbi) (60%) and divestiture (20%). In total, Bourne Partners Strategic Capital has invested in 3 US states and 3 different countries. Its largest (disclosed) acquisition occurred in 2017 when it acquired Inova Pharmaceuticals Pte for $930M.

In the last 3 years, Bourne Partners Strategic Capital has exited 1 company. The Firm’s most common exit type is secondary buyout (100%). Bourne Partners Strategic Capital’s largest (disclosed) exit occurred in 2022 when it sold Inova Pharmaceuticals Pte for $1.4B.

Join Mergr to view Bourne Partners Strategic Capital’s full profile and discover more small private equity firm investors just like it.

M&A Summary

  • M&A Total Activity6
    • M&A Buy Activity5
    • M&A Sell Activity1
  • Total Sectors Invested 2
  • Total Countries Invested 3
  • M&A Buy/Sell Connections 5

Bourne Partners Strategic Capital

Bourne Partners Strategic Capital

550 South Caldwell Street, Suite 900,
Charlotte, North Carolina 28202
United States
(704) 552-8407
www.bourne-partners.com

Bourne Partners Strategic Capital is the direct investment arm of financial advisory firm Bourne Partners. Strategic Capital looks to partner with other sponsors and management teams to pursue investment opportunities in the pharmaceutical and consumer health sectors. The Group targets a variety of investment situations and will consider transactions valued between $50 million and $1 billion. Bourne Partners Strategic Capital is based in Charlotte, North Carolina.


Investment Criteria

Sectors of Interest: Healthcare Services, Life Science

Target Transaction Types: Buyout (LBO, MBO, MBI)

Geographic Preferences: East US, Midwest US, South US, West US, United Kingdom, Australia/New Zealand

Transaction Criteria Min Max
Target Revenue - -
Target EBITDA - -
Investment Size - -
Enterprise Value - -

M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (0.0/yr) # 5 - - - - - 5
vol $930M $930M
Sell (0.2/yr) # - - - 1 - - 1
vol $1.4B $1.4B
  6

Most Recent M&A

Company Date Value Type
Inova Pharmaceuticals (Singapore) Pte Ltd. 2022-10-28 1.4B USD Secondary Sale
Singapore, Singapore · www.inovapharma.com
Pharmaceutical Associates, Inc. 2019-11-06 - Buyout (LBO, MBO, MBI)
Greenville, South Carolina · www.paipharma.com
Millicent Pharma Ltd. 2018-05-21 - Buyout (LBO, MBO, MBI)
Dundalk, Ireland
Inova Pharmaceuticals (Singapore) Pte Ltd. 2017-06-08 930M USD Divestiture
Singapore, Singapore · www.inovapharma.com
Curia Global, Inc. 2017-06-06 - Going Private
Albany, New York · www.curiaglobal.com
WellDyneRx LLC 2016-08-01 - Buyout (LBO, MBO, MBI)
Lakeland, Florida · www.welldynerx.com
View All >>

Portfolio M&A

Company Acquired Add-On/Sale Date #
Curia Global, Inc. 2017-06-06 Whitehouse Analytical Laboratories 2024-03-14 3
Albany, New York · www.curiaglobal.com Lebanon, New Jersey · www.whitehouselabs.com
Curia Global, Inc. 2017-06-06 LakePharma, Inc. 2021-07-14 2
Albany, New York · www.curiaglobal.com San Carlos, California · www.lakepharma.com
Curia Global, Inc. 2017-06-06 Integrity Bio, Inc. 2021-07-13 1
Albany, New York · www.curiaglobal.com Camarillo, California · www.integritybio.com
Millicent Pharma Ltd. 2018-05-21 AMAG Pharmaceuticals, Inc. - INTRAROSA Rights 2020-05-21 1
Dundalk, Ireland Waltham, Massachusetts · www.us.intrarosa.com
Curia Global, Inc. 2017-06-06 Archimica S.p.A. 2019-08-01 1
Albany, New York · www.curiaglobal.com Lodi, Italy · www.archimica.com

M&A by Sector

Sector Current # Value All-time # Value
Life Science 3 (75%) - 4 (80%) 930M (100%)
Healthcare Services 1 (25%) - 1 (20%) -
Total 4 - 5 $930M

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States 3 (75%) - 3 (60%) -
  South Carolina 1 (25%) - 1 (20%) -
  New York 1 (25%) - 1 (20%) -
  Florida 1 (25%) - 1 (20%) -
Ireland 1 (25%) - 1 (20%) -
Singapore - - 1 (20%) 930M (100%)
Total 4 - 5 $930M

Acquisitions by Deal Type

Type Current # Value All-time # Value
Buyout (LBO, MBO, MBI) 3 (75%) - 3 (60%) -
Divestiture - - 1 (20%) 930M (100%)
Going Private 1 (25%) - 1 (20%) -
Total 4 - 5 $930M

Exits by Deal Type

Type Total # Value
Secondary Sale 1 (100%) 1.4B (100%)
Total 1 $1.4B

Deal Values

buy # Total
$100M to $1B 1 $930M
TOTAL $930M
Largest Inova Pharmaceuticals (Singapore) Pte Ltd.
$930M (2017-06-08)
sell # Total
> $1B 1 $1.4B
TOTAL $1.4B
Largest Inova Pharmaceuticals (Singapore) Pte Ltd.
$1.4B (2022-10-28)

M&A Connections

Deals
Acquired from
Strategic(s)
20%
1 (20%)
Exited to
Investor(s)
100%
1 (100%)

Investor Summary

Investor Type

Private Equity Firm

Size

Small

Established

2001

Specialist/Generalist

Specialist

Leadership

Banks Bourne

Founder & CEO

F. Alexander (Xan) Smith

Managing Director of Business Development

Minor Hinson

Senior Managing Director & CIO

Jeremy Johnson

Senior Managing Director & Head of Investment Banking

Calli Lewis

Chief Of Staff

FAQ

When was Bourne Partners Strategic Capital founded?

Bourne Partners Strategic Capital was founded in 2001.

What type of investor is Bourne Partners Strategic Capital?

Bourne Partners Strategic Capital is a private equity firm.

Where is Bourne Partners Strategic Capital headquartered?

Bourne Partners Strategic Capital is headquartered in Charlotte, North Carolina.

 Subscribe to unlock this and 208,055
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 201K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Mergr

Product

Company

Legal